News & Analysis on Clinical Trial Services & Contract Research And Development
Copapharm Europe, the alliance of specialist packaging companies, has announced "healthy" sales figures for 2005, as its one-stop pan-European approach to the supply of pharmaceutical packaging equipment is becoming more popular.
As America desperately waited for its influenza vaccines, Chiron had to deal with major quality control issues between July and October 2005 at its troubled vaccine manufacturing plant in Liverpool according to a US Food and Drug Administration (FDA)...
DanioLabs has announced the start of a Phase I proof-of-concept trial of DL06001 and DL06002 for sialorrhoea (drooling) and hyperhidrosis (excessive sweating) in Parkinson's disease as the company aim to meet the need for treating these associated...
Bristol Myers Squibb (BMS) has announced that the European Commission has granted an approval for Baraclude (entecavir) for the treatment of chronic hepatitis B virus (HBV) infection.
Cambrex Bio Science has successfully completed its first monoclonal antibody project in the company's new cell culture bioreactor, as well as its first small-large molecule conjugation project.
Tripos has introduced its answer to rapid in-silico drug screening with its virtual screening software that uses a fully automatic flexible molecular docking algorithm to offer speed, accuracy and usability advantages over current methods.
A dry powder nasal flu vacccine is being hailed by its developers at DelSite Biotechnologies as a unique storage solution, providing delivery advantages over traditional flu vaccines in the event of a bird flu pandemic.
Chi-Med has been given the Food and Drug Administraton (FDA) green light to broaden its oncology drug candidate clinical trials after it exhibited encouraging results, which the company want to expand into a much wider patient population to fully...
The sale of Clariant's Pharmaceutical Fine Chemicals (PFC) to equity firm Towerbrook for around SFr110m (€70m) has been completed and the unit, now called Archimica, is determined to dominate the pharma raw materials market.
ExonHit Therapeutics was present at the PiperJaffray healthcare conference in London giving investors updates on company activity over the last year. The company are coming off the back of a patent application, which covers a number of genes that...